A UPenn Lab Just Cut HPV in Saliva by 93% — With Chewing Gum

A UPenn Lab Just Cut HPV in Saliva by 93% — With Chewing Gum

The headline almost reads as parody: a chewing gum that fights oral cancer. But Henry Daniell's team at the University of Pennsylvania School of Dental Medicine just published it in Scientific Reports — a bioengineered gum, made from lablab beans, that drops human papillomavirus levels in saliva by 93% in a single dose, and pushes two of the most cancer-linked oral bacteria to nearly zero.

Head and neck squamous cell cancer (HNSCC) is the kind of disease that punishes late detection — survival drops sharply once it's symptomatic, and HPV is now the leading driver of new cases. The Penn gum carries FRIL, a naturally antiviral protein from lablab beans, which neutralizes HPV directly in saliva — 93% reduction in saliva, 80% in oral rinse. Add protegrin, an antimicrobial peptide, and the same gum brings Porphyromonas gingivalis and Fusobacterium nucleatum — two bacteria that worsen oral-cancer outcomes — close to undetectable, while leaving the rest of the oral microbiome intact. That's the part that separates this from radiation therapy, which scours the helpful bacteria out alongside the harmful ones and leaves you with a yeast problem.

This isn't a detection tool. It's a prevention/adjuvant tool — a treatment that could be chewed alongside or after standard cancer therapy to keep the carcinogenic microbes that help drive recurrence under control. Daniell's team is calling for clinical trials.

Gobble's Take: Most cancer prevention tools require a hospital, a copay, or a syringe. This one's a piece of gum and your existing chewing reflex.

Sources: SciTechDaily · Scientific Reports

The FDA Is Closing the Peptide Window — And Biohackers Are Scrambling

The question circulating in longevity circles right now isn't whether the FDA will crack down on compounded and research peptides — it's how fast. Discussions on r/Biohacking are filling up with people asking what their plan is once BPC-157, TB-500, and similar compounds disappear from compounding pharmacies and grey-market research chemical suppliers. The FDA's concern centers on safety, contamination risk, and the fact that many of these peptides are being used therapeutically in humans despite having no approved indication for those uses.

The legal architecture holding this market together has always been fragile. Compounding pharmacies can legally produce certain drugs without full FDA approval, but the agency has the authority to restrict or ban specific compounds — and it has used that authority before. TB-500 (thymosin beta-4) has already been flagged. BPC-157, which many in the longevity community use for gut repair and injury recovery, sits in a similar gray zone. The "research chemical" loophole — selling peptides explicitly labeled as not for human consumption — is also under increasing scrutiny as regulators connect the dots between labeling and actual use.

For anyone who has built a longevity protocol around peptides, the window to consult a physician about legitimate prescribing pathways — or to understand what's actually at risk pharmacologically — is narrowing faster than most people realize.

Gobble's Take: The grey market gave the longevity community a five-year head start on peptide experimentation; the FDA is about to hand the bill back.

Sources: r/Biohacking · r/Biohacking

In Case You Missed It

Yesterday's top stories:

• One-Third of Americans Are Accelerating Their Aging Every Night — New CDC Report
• The Three Longevity Mistakes Doctors Say Are Derailing Even the Most Dedicated Biohackers
• 25% of the Planet Has Fatty Liver Disease and Most Don't Know It
• Bioregulators Are Being Used to Restore Testosterone — Without Shutting Down Your Own Production